Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer

Urology

Volumn 67, Issue 6, 2006, Pages 1247-1252

  Quek, Marcus L ^a   Daneshmand, Siamak ^b   Rodrigo, Sonali ^c   Cai, Jie ^c   Dorff, Tanya B ^c   Groshen, Susan ^c   Skinner, Donald G ^c   Lieskovsky, Gary ^c   Pinski, Jacek ^c  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CHROMOGRANIN A; PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE SYSTEM; PELVIS LYMPHADENECTOMY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE EPITHELIUM; PROSTATECTOMY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CHROMOGRANIN A; CHROMOGRANINS; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEUROSECRETORY SYSTEMS; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33744542743     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.12.009     Document Type: Article

References (30)

1. Abrahamsson P.A. Neuroendocrine differentiation in prostatic carcinoma. Prostate 39 (1999) 135-148
2. Jongsma J., Oomen M.H., Noordzij M.A., et al. Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate 42 (2000) 34-44
3. Bonkhoff H. Neuroendocrine cells in benign and malignant prostate tissue. morphogenesis, proliferation, and androgen receptor status. Prostate Suppl 8 (1998) 18-22
4. Vashchenko N., and Abrahamsson P.A. Neuroendocrine differentiation in prostate cancer. implications for new treatment modalities. Eur Urol 47 (2005) 147-155
5. Huss W.J., Gregory C.W., and Smith G.J. Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft. association with tumor cell proliferation prior to recurrence. Prostate 60 (2004) 91-97
6. di Sant'Agnese P.A., and Cockett A.T. Neuroendocrine differentiation in prostatic malignancy. Cancer 78 (1996) 357-361
7. Abrahamsson P.A., Falkmer S., Falt K., et al. The course of neuroendocrine differentiation in prostatic carcinomas. an immunohistochemical study testing chromogranin A as an "endocrine marker.". Pathol Res Pract 185 (1989) 373-380
8. Abrahamsson P.A., Wadstrom L.B., Alumets J., et al. Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract 182 (1987) 298-307
9. Guate J.L., Escaf S., Menendez C.L., et al. Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma. effect of hormonal treatment. Urol Int 59 (1997) 149-153
10. Krijnen J.L., Bogdanowicz J.F., Seldenrijk C.A., et al. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 158 (1997) 171-174
11. Jiborn T., Bjartell A., and Abrahamsson P.A. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 51 (1998) 585-589
12. 1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun 257 (1999) 609-614
13. Spiotto M.T., and Chung T.D. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 42 (2000) 186-195
14. Deeble P.D., Murphy D.J., Parsons S.J., et al. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 21 (2001) 8471-8482
15. Chen T., Cho R.W., Stork P.J., et al. Elevation of cyclic adenosine 3′,5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. Cancer Res 59 (1999) 213-218
16. Cox M.E., Deeble P.D., Bissonette E.A., et al. Activated 3′,5′-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line. J Biol Chem 275 (2000) 13812-13818
17. Shen R., Dorai T., Szaboles M., et al. Transdifferentiation of cultured human prostate cells to a neuroendocrine cell phenotype in a hormone-depleted medium. Urol Res 3 (1997) 67-75
18. Cohen R.J., Glezerson G., Haffejee Z., et al. Prostatic carcinoma. histological and immunohistological factors affecting prognosis. Br J Urol 66 (1990) 405-410
19. Weinstein M.H., Partin A.W., Veltri R.W., et al. Neuroendocrine differentiation in prostate cancer. enhanced prediction of progression after radical prostatectomy. Hum Pathol 27 (1996) 683-687
20. Theodorescu D., Broder S.R., Boyd J.C., et al. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 80 (1997) 2109-2119
21. Cohen M.K., Arber D.A., Coffield K.S., et al. Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer 74 (1994) 1899-1903
22. Noordzij M.A., van der Kwast T.H., van Steenbrugge G.J., et al. The prognostic influence of neuroendocrine cells in prostate cancer. results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 62 (1995) 252-258
23. Allen F.J., Van Velden D.J., and Heyns C.F. Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer?. Br J Urol 75 (1995) 751-754
24. Pruneri G., Galli S., Rossi R.S., et al. Chromogranin A and B and secretogranin II in prostatic adenocarcinomas. neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. Prostate 34 (1998) 113-120
25. Tan M.O., Karaoglan U., Celik B., et al. Prostate cancer and neuroendocrine differentiation. Int Urol Nephrol 31 (1999) 75-82
26. Daneshmand S., Quek M.L., Stein J.P., et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy. long-term results. J Urol 172 (2004) 2252-2255
27. Bostwick D.G., Qian J., Pacelli A., et al. Neuroendocrine expression in node positive prostate cancer. correlation with systemic progression and patient survival. J Urol 168 (2002) 1204-1211
28. Wang Q., Horiatis D., and Pinski J. Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation. Prostate 61 (2004) 253-259
29. Wang Q., Horiatis D., and Pinski J. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. Int J Cancer 111 (2004) 508-513
30. Aprikian A.G., Cordon-Cardo C., Fair W.R., et al. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 71 (1993) 3952-3965